Navigation Links
Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies

- New Studies Confirm That Fusion Proteins Made by Combining Cytokines With Peregrine's Anti-PS Antibodies Demonstrate Increased Anti-Tumor Activity With No Observable Toxicity -

LOS ANGELES and TUSTIN, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today reported that data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that fusion proteins combining the anti-cancer cytokines alpha interferon and interleukin 2 (IL-2) with 2aG4, a bavituximab equivalent, demonstrated potent anti-cancer activity in preclinical models of B-cell lymphoma and melanoma. In these studies, the antibody-cytokine fusion proteins generated a robust anti-tumor response without any observable toxicity. These immunocytokine fusion proteins incorporating antibodies that target the blood vessels of tumors are new preclinical candidates under Peregrine's proprietary Vascular Targeting Agent (VTA) technology platform.

The use of VTAs to deliver cytokines specifically to tumor targets is an appealing approach since the anti-cancer utility of cytokines such as interferons and interleukin 2 has been limited by their short half-life and the systemic toxicity seen at high doses. VTA immunocytokines aim to overcome these problems by combining the immunomodulatory activity of the cytokine with the tumor specificity of a targeted antibody.

In these proof of principle studies, VTA immunocytokines were created by combining type I interferon and interleukin 2 with 2aG4, an anti-phospholipid antibody similar to Peregrine's bavituximab. The resulting immunocytokine fusion proteins were capable of selectively targeting tumor blood vessels and displayed potent anti-cancer effects in a number of tumor models wit hout causing any observable toxicity. The studies also showed that different forms of the VTAs could be combined, and that the combination of 2aG4-IL-2 with 2aG4-alpha interferon was significantly more effective in inhibiting tumor growth than either agent alone. In a preclinical model of B-cell lymphoma, tumor growth was inhibited by 85% in the combination-treated group compared with 60% and 65% in animals treated with either 2aG4-IL-2 or 2aG4-alpha interferon, respectively.

"These new data reaffirm the broad potential and versatility of our Vascular Targeting Agent platform for cancer therapy," said Steven W. King, president and CEO of Peregrine. "We have long thought that our anti- phospholipid antibodies would be ideal for the delivery of cytokines for cancer therapy based on their inherent immunostimulatory effects combined with the anti-tumor effects of the cytokines themselves. We are especially pleased with the strong anti-tumor activity observed in a model of B-cell lymphoma, the first non-solid cancer we have successfully addressed using our VTA technology. We are now assessing our options to further develop and commercialize these cytokine fusion proteins for cancer and potentially, viral infections."

The new class of fusion protein agents falls under Peregrine's VTA technology platform for cancer therapy that includes over 200 patents and patent applications covering broad concepts of tumor therapy using agents that target tumor blood vessels. Because interferon is currently part of standard- of-care therapy for virus infections including chronic hepatitis C, Peregrine also intends to assess the utility of the new class as a second-generation treatment for viral infections.

This work was supported by Susan G. Komen for the Cure and a sponsored research agreement with Peregrine Pharmaceuticals Inc.

Number 3539: Inhibition of Tumor Growth by Targeting Cytokines to Phosphatidylserine (PS) on Tumor Vascular Endothelium, Xianming H uang, Dan Ye, Troy Luster, Jin He, Shuzhen Li, Linda Watkin, Janie Iglehart, Philip Thorpe, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs for HCV infection and a range of solid cancers in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that that the efficacy results of the B-cell lymphoma preclinical animal model will not correlate to the related efficacy studies in human clinical trials. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of produc t development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2006 and the quarterly report on Form 10-Q for the quarter ended January 31, 2007. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release

    Contacts:

    GendeLLindheim BioCom Partners

    Investors                                      Media

                              Barbara Lindheim

    (800) 987-8256                                 (212) 918-4650

info@peregrineinc.com

CONTACT: Investors, +1-800-987-8256, , or Media,Barbara Lindheim, +1-212-918-4650, both of GendeLLindheim BioCom Partners,for Peregrine Pharmaceuticals, Inc. info@peregrineinc.com

Web site: http://www.peregrineinc.com/

Ticker Symbol: (NASDAQ-NMS:PPHM)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):